John MBA - Harmony Biosciences CEO Pres
| HRMY Stock | USD 34.71 0.64 1.88% |
Insider
John MBA is CEO Pres of Harmony Biosciences Holdings
| Age | 57 |
| Address | 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462 |
| Phone | 484 539 9800 |
| Web | https://www.harmonybiosciences.com |
Harmony Biosciences Management Efficiency
The company has return on total asset (ROA) of 0.1285 % which means that it generated a profit of $0.1285 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2275 %, meaning that it created $0.2275 on every $100 dollars invested by stockholders. Harmony Biosciences' management efficiency ratios could be used to measure how well Harmony Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Harmony Biosciences' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.31 in 2024, whereas Return On Equity is likely to drop 0.26 in 2024. At this time, Harmony Biosciences' Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to rise to about 105.3 M in 2024, whereas Total Assets are likely to drop slightly above 466 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Rob Henderson | Viridian Therapeutics | N/A | |
| Mark Gowland | Fennec Pharmaceuticals | N/A | |
| Ron MBA | Nuvectis Pharma | 58 | |
| David Pompliano | Revolution Medicines | N/A | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Charles Winter | Janux Therapeutics | 55 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Andy Meyer | Janux Therapeutics | 40 | |
| Carrie MBA | Viridian Therapeutics | N/A | |
| Peter BSc | Syndax Pharmaceuticals | 55 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Tommy Diraimondo | Janux Therapeutics | 38 | |
| Behrad Derakhshan | Edgewise Therapeutics | 44 | |
| MA MS | Inozyme Pharma | N/A | |
| Richard Heyman | Syndax Pharmaceuticals | 67 | |
| Keith MBA | Keros Therapeutics | 54 | |
| Stephanie Yao | Kronos Bio | N/A | |
| Anne McKay | Fennec Pharmaceuticals | 70 | |
| Johannes Hull | Pliant Therapeutics | 49 | |
| Kevan Shokat | Revolution Medicines | N/A | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 |
Harmony Biosciences Leadership Team
Elected by the shareholders, the Harmony Biosciences' board of directors comprises two types of representatives: Harmony Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Harmony. The board's role is to monitor Harmony Biosciences' management team and ensure that shareholders' interests are well served. Harmony Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Harmony Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Audrey Murphy, Head Resources | ||
| David Bradshaw, Head Operations | ||
| Cate McCanless, Head Policy | ||
| Brennan Doyle, VP Relations | ||
| MBA JD, Executive Officer | ||
| Audrey SPHR, Head Resources | ||
| Jeffrey Aronin, Founder Chairman | ||
| Tricia Glover, Chief Officer | ||
| Jeffrey MD, CEO President | ||
| MS MD, Executive Officer | ||
| Christian Ulrich, General Secretary | ||
| John MBA, CEO Pres | ||
| Sharon Goldbach, Head Admin | ||
| Christian JD, General Secretary | ||
| Jeffrey MBA, Executive Officer | ||
| Luis Sanay, Head Relations |
Harmony Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Harmony Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Shares Owned By Insiders | 11.62 % | ||||
| Shares Owned By Institutions | 92.84 % | ||||
| Number Of Shares Shorted | 6.06 M | ||||
| Price To Earning | 293.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.